Sharinky If Dr Reddy’s wins on their claim they are not infringing by selling to pts for less then 12 weeks then generic V becomes available and pts regardless of indication will get the least expensive equivalent molecule which will be a generic V and Amarin loses almost all its US revenue.
If Dr Reddy wins their claim that the IP was obvious and therefore the patents are invalid then generic V can be sold and Amarin loses almost all its US revenue.
They only have to be successful with 1 claim to win the entire US market.